文献速递瓣膜病与结构性心脏病

主动脉瓣狭窄合并二尖瓣反流:心脏瓣膜协作组多瓣膜病研讨会要点

Aortic Stenosis and Mitral Regurgitation: Takeaways From the Heart Valve Collaboratory Workshop on Multivalvular Disease.
PubMed 文献 · J Am Coll Cardiol · 2025-06-27

本文汇总2024年心脏瓣膜协作组(HVC)研讨会关于主动脉瓣狭窄合并二尖瓣反流的核心见解,阐述疾病负担、现有外科与经导管治疗的局限及临床决策差异,并聚焦患者选择、干预时机与顺序、影像学及经导管主动脉瓣置换术后二尖瓣反流反应预测等未满足需求,提出前瞻性注册研究、随机试验及人工智能应用等研究议程。

要点

  • 主动脉瓣狭窄合并二尖瓣反流因血流动力学交互复杂且指南推荐有限,临床管理面临挑战。
  • 研讨会聚焦患者选择、干预时机与顺序、影像学及TAVR后二尖瓣反流反应预测等未满足需求。
  • 提出建立前瞻性注册研究、比较分期与同期治疗的随机试验及人工智能用于影像分析和风险预测的研究议程。

核心结论

  • 多瓣膜病管理需通过多学科协作、前瞻性注册研究和随机试验来推进标准化与个性化治疗。

研究设计与样本

  • 本文为JACC与心脏瓣膜协作组(HVC)首次合作的一部分,汇总2024年HVC研讨会关于主动脉瓣狭窄合并二尖瓣反流的见解。

主要发现

  • 当前外科和经导管方法存在局限,临床决策因证据缺口而存在差异。
  • 研讨会识别了患者选择、干预时机与顺序、影像学及TAVR后二尖瓣反流反应预测等方面的未满足需求。

临床怎么用

  • 临床中应关注主动脉瓣狭窄合并二尖瓣反流患者的干预时机与顺序选择,并重视TAVR后二尖瓣反流反应的预测。

局限性

  • 原文指出当前指南推荐有限且证据存在缺口,研讨会成果基于专家共识而非系统评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of multivalvular disease presents increasing challenges in clinical practice caused by complex hemodynamic interactions and limited guideline-based recommendations. As part of the inaugural collaboration between JACC and the Heart Valve Collaboratory (HVC), this paper synthesizes key insights from the 2024 HVC workshop focused on concomitant aortic stenosis + mitral regurgitation. The document outlines the burden of disease, limitations of current surgical and transcatheter approaches, and variability in clinical decision-making caused by gaps in evidence. A major focus of the workshop was identifying unmet needs in patient selection, timing and sequencing of interventions, imaging, and prediction of mitral regurgitation response after transcatheter aortic valve replacement. The paper highlights unresolved clinical questions and proposes a research agenda including the establishment of prospective registries, randomized trials comparing staged vs concomitant therapy, and use of artificial intelligence for imaging analysis and risk prediction. By bringing together multidisciplinary expertise and outlining priorities for future investigation, this initiative seeks to advance the standardization and personalization of multivalvular disease management. These efforts aim to improve outcomes for patients with complex valve disease and serve as a framework for addressing other multivalve combinations in future research.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Zaid S, Ng V, Hahn RT, et al. Aortic Stenosis and Mitral Regurgitation: Takeaways From the Heart Valve Collaboratory Workshop on Multivalvular Disease. J Am Coll Cardiol. 2025. PMID: 40576596. doi:10.1016/j.jacc.2025.05.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。